Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Ipilimumab in PD-1 Refractory Melanoma
NCT02743819Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Jun 2016
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and ipilimumab in melanoma, sponsored by University of Chicago. Primary endpoint: Overall Response Rate Per irRECIST at 16 weeks. Started Jun 2016; status: active, not recruiting.
02
Drugs
pembrolizumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02743819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743819.